RAPIDe-3
92 evidence topics · 15 sources
Objective
Trial aim
Objective stated in the AAAAI 2026 results poster
Location and study date
Sites, countries, and enrollment period in the publication
Patient association input on countries and sites
Trial initiation and topline timing reported by the company
Target enrollment reached
Topline announcement date
Study design
Crossover design, randomization, and stratification
Masking and study drug packaging
Non-attack pharmacokinetic dose in adolescents
Electronic patient-reported outcomes and attack qualification by the investigator
Registry design details
| Field | Reported value |
|---|---|
| Other study ID number | “PHA022121-C306” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “Quadruple” |
Eligibility criteria
Inclusion criteria in the publication
Exclusion criteria in the publication
Registry inclusion criteria
Registry exclusion criteria: organ function, CYP3A4 medicines, and prior therapies
Qualifying attacks and exclusion of severe laryngeal attacks
Treatment
Registry treatment sequences and intervention
Self-administration after investigator qualification
Second capsule and rescue medication rules
Study outcomes
Rationale for using time to onset of symptom relief by patient global impression of change as the primary endpoint
Primary endpoint: registry definition and time frame
PGI-C and PGI-S scales
Selection of PGI-C for the primary endpoint: mixed methods patient-reported outcome study
“When comparing different definitions of time to onset of symptom relief, PGI-C had greater sensitivity in detecting early symptom relief yet remained comparable to AMRA symptom relief endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the PGI-C, participants (n = 19) discussed perceived meaningful improvement from their worst score and associated this with a reduction or improvement in symptoms and knowledge the attack would not worsen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of the association between AMRA and PGI-C established in this study, the phase 3 RAPIDe-3 trial used the PGI-C to define the primary efficacy endpoint.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PGI-C rating of a little better as a clinically meaningful milestone: patient interviews and phase 2 sebetralstat data
“Patient interviews revealed a strong preference (71%) for the Patient Global Impression of Change (PGI‐C) over other measures and indicated a rating of "A Little Better" as a clinically meaningful milestone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Feedback from a patient advisory board initially identified the PGI‐C as a preferred PRO for assessing symptom relief in HAE, and follow‐up structured interviews highlighted that the rating of "A Little Better" on the PGI‐C best represented the earliest signs of symptom relief for most patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Core outcome set for trials of acute treatment
“In the second round, a consensus of 90% or greater was achieved on a core outcome set consisting of five key outcomes: change in overall symptom severity at one predetermined time point between 15 minutes and 4 hours after treatment, time to end of progression of all symptoms, the need for rescue medication during the entire attack, impairment of daily activities, and treatment satisfaction.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Conformance of RAPIDe-3 endpoints with the AURORA core outcome set
Key secondary endpoints: definitions in the publication
Key secondary endpoints: first six in the testing hierarchy
Key secondary endpoints: registry definitions
Key secondary endpoint: end of progression, definition and rationale
Key secondary endpoint: end of progression, psychometric validation with RAPIDe-3 data
Key secondary endpoints measured with the angioedema symptom rating scale
Safety endpoints and the 3-day reporting window
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size calculation and planned enrollment
Planned enrollment stated by the company, May 2025
Registry actual enrollment
Participants and attacks analyzed in each analysis set
Safety analysis set by treatment received
Observed placebo response compared with the sample size assumption
Description of analysis sets
Primary efficacy, expanded, and safety analysis sets
Statistical tests for time-to-event and binary endpoints
Multiplicity control by fixed-sequence gatekeeping
Intercurrent events and missing data: composite variable strategy
Supplementary analyses: per-protocol set and treatment policy strategy
Results
Participant disposition
Screening, randomization, and treated attacks
Randomized sequences and attacks treated in each sequence
“N=134 enrolled (124 adults, 10 adolescents)” (opens the source at this quote in a new tab)
“N=68 randomized to placebo” (opens the source at this quote in a new tab)
“N=53 treated one attack with placebo” (opens the source at this quote in a new tab)
“N=41 treated one attack with deucrictibant” (opens the source at this quote in a new tab)
“N=66 randomized to deucrictibant” (opens the source at this quote in a new tab)
“N=60 treated one attack with deucrictibant” (opens the source at this quote in a new tab)
“N=47 treated one attack with placebo” (opens the source at this quote in a new tab)
“N=88 paired attacks (Primary Efficacy Analysis Set)” (opens the source at this quote in a new tab)
Trial closure before all participants treated two attacks
Baseline characteristics
All randomized participants: sex, age, and HAE with normal C1 inhibitor
All randomized participants: demographic and disease characteristics, 134 participants
| Characteristic | All randomized participants (N=134) |
|---|---|
| Age in years, mean (SD) | “39.0 (14.7)” |
| Age ≥12 to <18 years, n (%) | “10 (7.5)” |
| Age ≥18 to <65 years, n (%) | “116 (86.6)” |
| Age ≥65 years, n (%) | “8 (6.0)” |
| Female, n (%) | “76 (56.7)” |
| BMI, mean (SD) | “26.5 (5.9)” |
| White, n (%) | “93 (69.4)” |
| Asian, n (%) | “19 (14.2)” |
| Black or African American, n (%) | “10 (7.5)” |
| Europe, n (%) | “56 (41.8)” |
| Rest of world, n (%) | “40 (29.9)” |
| North America, n (%) | “38 (28.4)” |
| Years since HAE diagnosis, mean (SD) | “17.7 (13.0)” |
| Attacks within 3 months before screening, mean (SD) | “4.4 (3.3)” |
| HAE-C1INH type 1, n (%) | “118 (88.1)” |
| HAE-C1INH type 2, n (%) | “10 (7.5)” |
| Unspecified HAE-C1INH type 1 or 2, n (%) | “2 (1.5)” |
| HAE-nC1INH, n (%) | “4 (3.0)” |
| Current long-term prophylaxis use, n (%) | “31 (23.1)” |
Participants with at least one treated attack: demographic and disease characteristics by treatment, 113 participants
“Participants may be represented in multiple columns.” (opens the source at this quote in a new tab)
Primary efficacy analysis set: demographic and disease characteristics, 88 participants
| Characteristic | Primary efficacy analysis group (N=88) |
|---|---|
| Age in years, mean (SD) | “38.7 (13.6)” |
| Age ≥12 to <18 years, n (%) | “5 (5.7)” |
| Age ≥18 to <65 years, n (%) | “80 (90.9)” |
| Age ≥65 years, n (%) | “3 (3.4)” |
| Female, n (%) | “47 (53.4)” |
| North America, n (%) | “19 (21.6)” |
| Europe, n (%) | “38 (43.2)” |
| Rest of world, n (%) | “31 (35.2)” |
| Years since HAE diagnosis, mean (SD) | “17.3 (12.24)” |
| HAE-C1INH type 1, n (%) | “79 (89.8)” |
| HAE-C1INH type 2, n (%) | “8 (9.1)” |
| Unspecified HAE-C1INH type 1 or 2, n (%) | “1 (1.1)” |
| Current long-term prophylaxis use, n (%) | “18 (20.5)” |
Attack type, location, and severity at pre-treatment, 201 treated attacks
Efficacy results
Primary endpoint: time to onset of symptom relief, primary efficacy analysis set of 88 participants with paired attacks
Primary and secondary endpoints by PGI-C and PGI-S, primary efficacy analysis set of 88 participants with paired attacks
| Endpoint and statistic | Deucrictibant N' | Deucrictibant result | Placebo N' | Placebo result | p value |
|---|---|---|---|---|---|
| Primary: time to onset of symptom relief (PGI-C), median time (95% CI), h | “83/88” | “1·28 (1·05 to 1·52)” | “87/88” | “>12 (5·82 to >12)” | “<0·0001” |
| Attacks meeting onset of symptom relief at 4 hours (PGI-C), n (%) | “83/88” | “69/83 (83%)” | “87/88” | “24/87 (28%)” | “<0·0001” |
| Time to substantial symptom relief (PGI-C), median time (95% CI), h | “83/88” | “2·85 (2·08 to 3·35)” | “87/88” | “>12 (10·30 to >12)” | “<0·0001” |
| Time to reduction in attack severity (PGI-S), median time (95% CI), h | “83/88” | “2·41 (1·70 to 2·98)” | “84/88” | “>12 (12·34 to >12)” | “<0·0001” |
| Time to complete symptom resolution (PGI-S), median time (95% CI), h | “83/88” | “11·95 (8·61 to 21·79)” | “87/88” | “>48 (>48 to >48)” | “<0·0001” |
| Time to end of progression (PGI-C), median time (95% CI), min | “83/88” | “17·47 (16·27 to 19·17)” | “87/88” | “228·67 (61·82 to 599·60)” | “<0·0001” |
| Complete symptom resolution with one dose at 24 hours (PGI-S), n (%) | “83/88” | “50/83 (60%)” | “87/88” | “13/88 (15%)” | “<0·0001” |
Secondary endpoints by PGI-C and PGI-S: median times, primary efficacy analysis set
Company summary of the primary and secondary results, efficacy analysis of 88 participants with paired attacks
Time to complete symptom resolution, placebo median: topline statement, December 2025, superseded in March 2026
End of progression median stated at NDA acceptance, July 2026
Secondary endpoints by AMRA, primary efficacy analysis set
Attacks reaching each endpoint within its prespecified timeframe, primary efficacy analysis set
Single capsule and second capsule use, primary efficacy analysis set of 88 paired attacks
Rescue medication use, primary efficacy analysis set
| Endpoint | Deucrictibant (n=88) | Placebo (n=88) | p value |
|---|---|---|---|
| Attacks using conventional on-demand therapy as rescue medication within 24 h, n (%) | “8/88 (9%)” | “39/88 (44%)” | “<0·0001” |
Complete symptom resolution with a single capsule at 24 hours, primary efficacy analysis set
Sustained response and single-capsule use among responding attacks, primary efficacy analysis set of 88 participants
Sensitivity and supplementary analyses, 113 participants with at least one treated attack
Subgroups by age, HAE type, long-term prophylaxis, and attack location and severity, participants with at least one treated attack
HAE with normal C1 inhibitor: two participants with one deucrictibant-treated attack each
Regional subgroups, North America and Europe or rest of world: all participants with treated attacks
| Region and endpoint | Deucrictibant | Placebo |
|---|---|---|
| North America: time to onset of symptom relief, median | “1.20 hours (95% CI: 0.84, 1.84)” | “6.55 hours (95% CI: 1.88, >12)” |
| Europe/Rest of World: time to onset of symptom relief, median | “1.28 hours (95% CI: 1.04, 1.41)” | “>12 hours (95% CI: 5.74, >12)” |
| North America: time to reduction in attack severity, median | “2.43 hours (95% CI: 1.03, 5.12)” | “>12 hours (95% CI: 2.65, >12)” |
| Europe/Rest of World: time to reduction in attack severity, median | “2.53 hours (95% CI: 1.70, 2.98)” | “>12 hours (95% CI: 12.10, >12)” |
| North America: time to complete symptom resolution, median | “11.61 hours (95% CI: 2.94, 26.14)” | “>48 hours (95% CI: 17.21, >48)” |
| Europe/Rest of World: time to complete symptom resolution, median | “12.04 hours (95% CI: 8.64, 21.79)” | “>48 hours (95% CI: >48, >48)” |
| North America: onset of symptom relief at 4 hours | “77.8% (n=14/18)” | “46.2% (n=12/26)” |
| Europe/Rest of World: onset of symptom relief at 4 hours | “84.6% (n=66/78)” | “26.4% (n=19/72)” |
Pharmacokinetics in adolescents: ten participants in a non-attack state
Health-related quality of life and patient-reported outcomes
In-trial qualitative interviews: design and sample of 91 participants
In-trial qualitative interviews: attack-related impacts on health-related quality of life
In-trial qualitative interviews: on-demand treatments used before enrollment
Safety results
Treatment-emergent adverse events, safety analysis set
| Event category | Non-attack deucrictibant (n=10): participants, n (%) | Non-attack: events, n | Treated attack deucrictibant (n=100): participants, n (%) | Deucrictibant: events, n | Treated attack placebo (n=101): participants, n (%) | Placebo: events, n |
|---|---|---|---|---|---|---|
| Any treatment-emergent adverse event | “3 (30%)” | “4” | “24 (24%)” | “40” | “17 (17%)” | “22” |
| Any treatment-emergent adverse event related to study drug | “0” | “0” | “5 (5%)” | “6” | “1 (1%)” | “1” |
| Any serious treatment-emergent adverse event | “0” | “0” | “1 (1%)” | “1” | “1 (1%)” | “1” |
| Any serious treatment-emergent adverse event related to study drug | “0” | “0” | “0” | “0” | “0” | “0” |
| Any severe treatment-emergent adverse event | “0” | “0” | “1 (1%)” | “2” | “1 (1%)” | “3” |
| Any severe treatment-emergent adverse event related to study drug | “0” | “0” | “0” | “0” | “0” | “0” |
| Any treatment-emergent adverse event within 3 days post-treatment | “0” | “0” | “15 (15%)” | “17” | “2 (2%)” | “3” |
| Treatment-emergent adverse event within 3 days related to study drug | “0” | “0” | “5 (5%)” | “6” | “1 (1%)” | “1” |
| Any serious treatment-emergent adverse event within 3 days post-treatment | “0” | “0” | “0” | “0” | “0” | “0” |
| Any severe treatment-emergent adverse event within 3 days post-treatment | “0” | “0” | “0” | “0” | “0” | “0” |
| Treatment-emergent adverse event leading to trial or study drug discontinuation | “0” | “0” | “0” | “0” | “0” | “0” |
| Treatment-emergent adverse event leading to death | “0” | “0” | “0” | “0” | “0” | “0” |
| Fatigue within 3 days post-treatment | “0” | “0” | “2 (2%)” | “2” | “0” | “0” |
Overall and 3-day adverse event rates, safety analysis set
Treatment-related adverse events
Serious and severe adverse events
Maximum severity grade of treatment-emergent adverse events, safety analysis set
| Participants with ≥1 TEAE by maximum grade | Placebo (N=101) | Deucrictibant (N=100) |
|---|---|---|
| Any TEAEs | “17 (16.8)” | “24 (24.0)” |
| Maximum Grade 1 (Mild) | “10 (9.9)” | “13 (13.0)” |
| Maximum Grade 2 (Moderate) | “6 (5.9)” | “10 (10.0)” |
| Maximum Grade 3 (Severe) | “0” | “1 (1.0)” |
| Maximum Grade 4 (Life-threatening) | “1 (1.0)” | “0” |
| Maximum Grade 5 (Fatal) | “0” | “0” |
Laboratory, vital sign, and electrocardiogram findings and discontinuations
Capsule ingestion during abdominal and laryngeal attacks
Study limitations
Summary
- The authors stated that “Limitations of this trial include the lack of attack stratification according to location and severity”, and that a larger proportion of severe attacks was therefore observed in the placebo group: severe or very severe attacks at pre-treatment were 17 (17%) of 101 deucrictibant-treated and 29 (29%) of 100 placebo-treated attacks. Two non-severe laryngeal attacks were treated with deucrictibant and none with placebo.
- Severe laryngeal attacks were not included, because of the risks of random assignment to double-masked placebo, and adolescents were instructed to treat laryngeal attacks of any severity with conventional on-demand therapy.
- The sponsor ended the trial after the prespecified number of participants with paired attacks was reached and before all participants had treated two attacks. Of 134 enrolled participants, 113 treated at least one attack and 88 contributed paired attacks to the primary efficacy analysis. One participant randomized to the deucrictibant-placebo sequence was given placebo in error and treated no second attack.
- Each participant treated at most one attack with deucrictibant in the crossover, and safety comparisons were descriptive. Treatment-emergent adverse events within 3 days of study drug were considered temporally clinically relevant.
- Subgroups were small: ten (7%) enrolled participants were adolescents, five of them in the primary efficacy analysis set, and only two unpaired attacks were recorded in participants with hereditary angioedema with normal C1 inhibitor.
- Eligibility required experience effectively using conventional on-demand therapy and excluded people older than 75 years, people with abnormal hepatic function or eGFR <60 ml/min/1.73 m2, users of strong CYP3A4 inhibitors or inducers, people with prior gene therapy, and pregnant or breastfeeding women.
- Use of rescue or selected prohibited medication was counted as treatment failure, and missing data at the end of follow-up were handled by right censoring without imputation.
- Health-related quality of life outcomes were exploratory endpoints planned for separate publication.